Latest Financial Health News

Kinetiko Energy reports mixed results from its five-well gas production test program, with the first well underperforming but the company maintaining optimism for the remaining wells and a strong financial footing.

Emperor Energy Limited reported a net operating cash outflow of $376,000 for the December quarter but bolstered its cash reserves with a $3.6 million financing inflow, ending the period with $3.4 million in cash.

Opthea Limited reports steady progress in its Phase 3 trials for sozinibercept, a novel treatment for wet AMD, supported by a strong cash position and a recent R&D tax incentive.

AGUIA RESOURCES LTD posted a $1.31 million net cash outflow for the December 2024 quarter, driven by exploration and evaluation expenses, while preparing for underground operations at its Santa Barbara Mine.

Po Valley Energy Limited reports a robust December 2024 quarter marked by rising gas production, strong revenue growth, and significant progress in exploration and development across its Italian assets.

Comet Ridge has made significant strides in its Mahalo Gas Hub development, approving upstream FEED and progressing pipeline connections, supported by a strong cash position of $19.3 million. These developments position the company to address Australia's tightening east coast gas market.

Botanix Pharmaceuticals has initiated the commercial rollout of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, with first prescriptions dispensed and a fully trained sales force deployed. The company anticipates meaningful revenue growth starting in the first quarter of 2025, backed by strong payer contracts and a robust cash position.

Hartshead Resources reports a robust December quarter with strategic progress on UK gas developments, fiscal clarity from government levy changes, and the acquisition of new licenses boosting its resource base.

Eden Innovations Ltd reports a striking 158% increase in US OptiBlend® sales for Q2 FY25, alongside expanding international traction for its EdenCrete® products and strategic property sales aimed at debt reduction.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

ResMed Inc. has announced a quarterly ordinary dividend of USD 0.053 per share for holders of its ASX-listed Chess Depositary Instruments, with payments scheduled for March 2025.

BetMakers Technology Group reports a sharp 69% reduction in adjusted EBITDA loss and a 43% improvement in operating cash flow for Q2 FY25, marking a pivotal shift from restructuring to growth. The company’s successful Apollo platform migration and cost-cutting initiatives underpin a confident outlook for revenue expansion.